Literature DB >> 8808700

Association of extended in vitro proliferative potential with loss of p16INK4 expression.

J R Noble1, E M Rogan, A A Neumann, K Maclean, T M Bryan, R R Reddel.   

Abstract

This study addresses the question of whether loss of p16INK4 expression contributes to the immortalization of human cells. In vitro immortalization usually proceeds through two phases. In the first phase (lifespan extension), cells continue proliferating and their telomeres continue shortening beyond the point at which normal cells become senescent. In the second phase (immortalization), the cells activate a telomere maintenance mechanism and acquire an unlimited proliferative potential. It has previously been shown that immortalized cells containing viral oncoproteins that bind and inactivate p110RB contain wild-type p16INK4; we therefore examined the p16INK4 status of cell lines that became immortalized in vitro in the absence of these oncoproteins. Three such lines were identified: III-CF/.2A1 and III-CF/E6A2 (both derived from Li-Fraumeni syndrome fibroblasts, probably by spontaneous immortalization) and MePV-231 (normal mesothelial cells transfected with HPV-16 E6/E7 genes that underwent deletion of these genes before immortalization). In each case p16INK4 expression was lost at or before immortalization. Further, a cell strain was identified that had an extended but finite lifespan associated with loss of p16INK4 (and p53) expression. Thus loss of p16INK4 expression was associated with extended in vitro lifespan but was not sufficient for immortalization, even in the absence of wild-type p53.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8808700

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Immortalization of mutant p53-transfected human fibroblasts by treatment with either 4-nitroquinoline 1-oxide or X-rays.

Authors:  K Kino; K Fushimi; C Gao; T Shima; K Mihara; M Namba
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-09       Impact factor: 2.416

2.  Genetic and epigenetic changes in human epithelial cells immortalized by telomerase.

Authors:  D G Farwell; K A Shera; J I Koop; G A Bonnet; C P Matthews; G W Reuther; M D Coltrera; J K McDougall; A J Klingelhutz
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

3.  Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest.

Authors:  D J Wong; S A Foster; D A Galloway; B J Reid
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

4.  Inactivation of p16 in human mammary epithelial cells by CpG island methylation.

Authors:  S A Foster; D J Wong; M T Barrett; D A Galloway
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

5.  The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

Authors:  F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

6.  Modeling mutations in the G1 arrest pathway in human gliomas: overexpression of CDK4 but not loss of INK4a-ARF induces hyperploidy in cultured mouse astrocytes.

Authors:  E C Holland; W P Hively; V Gallo; H E Varmus
Journal:  Genes Dev       Date:  1998-12-01       Impact factor: 11.361

7.  Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts.

Authors:  E C Burt; L A James; M J Greaves; J M Birch; J M Boyle; J M Varley
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

8.  Doxycycline-Regulated p16MTS1 Expression Suppresses the Anchorage-Independence and Tumorigenicity of Breast Cancer Cell Lines that Lack Endogenous p16.

Authors:  Maria C Todd; Thomas A Langan; Robert A Sclafani
Journal:  J Cancer       Date:  2017-01-13       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.